Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury.

Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Ricciardelli B, Donnarumma E, Bianco A, Zabatta MA, Troncone G, Colombo A, Briguori C, Condorelli G.

Circulation. 2012 Dec 18;126(25):3008-16. doi: 10.1161/CIRCULATIONAHA.112.103317. Epub 2012 Nov 12.

2.

Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.

Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G; REMEDIAL II Investigators..

Circulation. 2011 Sep 13;124(11):1260-9. doi: 10.1161/CIRCULATIONAHA.111.030759. Epub 2011 Aug 15.

3.

Atorvastatin ameliorates contrast medium-induced renal tubular cell apoptosis in diabetic rats via suppression of Rho-kinase pathway.

Su J, Zou W, Cai W, Chen X, Wang F, Li S, Ma W, Cao Y.

Eur J Pharmacol. 2014 Jan 15;723:15-22. doi: 10.1016/j.ejphar.2013.10.025. Epub 2013 Oct 24.

PMID:
24445019
4.

[Atorvastatin attenuated contrast induced renal function damage].

Chen GL, Su JZ.

Zhonghua Xin Xue Guan Bing Za Zhi. 2009 May;37(5):389-93. Chinese.

PMID:
19781210
5.

[Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].

Su JZ, Xue Y, Cai WQ, Huang QY, Chai DJ, Chen GL, Wang FB, Chen XP, Zhang DS.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Sep;39(9):807-11. Chinese.

PMID:
22321227
6.

Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.

Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F.

Am J Cardiol. 2010 Feb 1;105(3):288-92. doi: 10.1016/j.amjcard.2009.09.026. Epub 2009 Dec 21.

PMID:
20102936
7.

N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial.

Heguilén RM, Liste AA, Payaslian M, Ortemberg MG, Albarracín LM, Bernasconi AR.

Clin Exp Nephrol. 2013 Jun;17(3):396-404. doi: 10.1007/s10157-012-0722-3. Epub 2012 Nov 10.

PMID:
23138396
8.

Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.

Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A.

J Am Coll Cardiol. 2009 Dec 1;54(23):2157-63. doi: 10.1016/j.jacc.2009.07.005. Epub 2009 Aug 6.

9.

Contrast-induced acute kidney injury: the continuous quest for pharmacological prevention.

Moscucci M.

Circ Cardiovasc Interv. 2012 Dec;5(6):741-3. doi: 10.1161/CIRCINTERVENTIONS.112.976126. No abstract available.

10.

Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes.

Paulsen L, Matthesen SK, Bech JN, Starklint J, Pedersen EB.

J Clin Pharmacol. 2010 Jul;50(7):816-22. doi: 10.1177/0091270009350627. Epub 2010 Jan 7.

PMID:
20056802
11.

Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.

Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S231-5.

12.
13.

Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin.

Li M, Liu Y, Dutt P, Fanburg BL, Toksoz D.

Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L463-71. Epub 2007 Jun 1.

14.

Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.

Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, Geng W, Gu X, Hao G, Jiang Y, Fan W, Wu W, Li S.

Cardiology. 2012;122(3):195-202. doi: 10.1159/000339472. Epub 2012 Jul 31.

PMID:
22854323
15.

Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.

Phoon RK, Kitching AR, Jones LK, Holdsworth SR.

Nephrology (Carlton). 2009 Oct;14(7):650-7. doi: 10.1111/j.1440-1797.2009.01141.x.

PMID:
19796023
16.

Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.

Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S, Alemdar R.

Angiology. 2010 Oct;61(7):711-4. doi: 10.1177/0003319710364216. Epub 2010 Apr 14.

PMID:
20395226
17.

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A.

J Am Coll Cardiol. 2009 Aug 4;54(6):558-65. doi: 10.1016/j.jacc.2009.05.028. Epub 2009 Jul 2.

18.

Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: updated study-level meta-analysis of 13 randomized controlled trials.

Lee JM, Park J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW, Kang HJ, Koo BK, Jo SH, Kim HS.

PLoS One. 2014 Nov 4;9(11):e111397. doi: 10.1371/journal.pone.0111397. eCollection 2014.

19.
20.

Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.

Li H, Li X, Ma H, Wang Y, Fu N, Jin D, Cong H.

ScientificWorldJournal. 2014 Jan 29;2014:565367. doi: 10.1155/2014/565367. eCollection 2014.

Supplemental Content

Support Center